Editor's Picks
Acadia Pharma (ACAD) Remlifanserin Trial Miss, Targets Cut
September 25, 2026Acadia Pharmaceuticals (NASDAQ: ACAD) Faces Remlifanserin Trial Miss as Analysts Cut Price Targets Analysts lowered price targets for Acadia Pharmaceuticals (NASDAQ: ACAD) after its Phase II RADIANT study for remlifanserin...
We will not share your information & you can unsubscribe at any time. You agree to our terms of service & privacy policy. You agree to receive emails & correspondence from Nextmemealert.
